other material
confidence high
sentiment positive
materiality 0.85
AbCellera announces U.S. government purchase of 614,000 doses of bamlanivimab/etesevimab for $1.29B
AbCellera Biologics Inc.
- Lilly will supply 614,000 additional doses no later than January 31, 2022; minimum 400,000 by December 31, 2021.
- Total agreement value is $1.29 billion for bamlanivimab with etesevimab, discovered by AbCellera.
- The antibody therapy has treated over 535,000 patients in the U.S., potentially preventing 25,000 hospitalizations.
- AbCellera receives royalties from Lilly on sales of bamlanivimab and etesevimab.